#USA #New York #Class Action #Levi & Korsinsky #Geron Corporation

Geron Corporation Class Action Notice

Levi & Korsinsky, LLP has alerted investors of Geron Corporation (NASDAQ: GERN) regarding an ongoing class action lawsuit. The firm aims to support those who suffered losses due to alleged securities fraud during a specific timeframe, from June 7, 2024, to February 25, 2025.

Class Action Overview

The lawsuit is focused on the claims made by the defendants, who allegedly misled investors about their drug, Rytelo (imetelstat), and its expected market performance. The company had asserted its confidence in the drug's launch and market potential, downplaying various risks associated with it, including the significant monitoring requirements and existing market competition. Investors relied on these statements but were misled about the actual risk factors correlating with the product's commercial success.

Background and Consequences

On February 26, 2025, Geron released disappointing financial results revealing a stagnation in Rytelo's growth. The announcement cited multiple factors, including seasonal impacts, increased competition, and a lack of awareness among potential prescribers. The revelation led to a startling 32.07% drop in Geron's stocks, plummeting from $2.37 to $1.61 per share, indicating a significant financial loss for its investors.

Next Steps for Investors

Geron Corporation investors who faced losses during the specified period have until May 12, 2025, to apply to become the lead plaintiff in the class action. However, participating in the lawsuit does not necessitate serving as a lead plaintiff, simplifying the process for affected shareholders.

If you are a class member, you may be eligible for compensation without any direct costs. It highlights the legal firm’s commitment to protecting investors’ rights while taking a no-cost approach to litigate these complex cases.

The Expertise of Levi & Korsinsky

For more than two decades, Levi & Korsinsky has excelled in representing shareholders in complex securities litigation. Their noteworthy track record includes recovering hundreds of millions for investors through successful litigation outcomes. They've consistently ranked in the top tier of securities litigation firms, underscoring their reputation for winning high-stakes cases.

For those interested in learning more or wanting to connect with the firm, they can reach out via email at [email protected] or call (212) 363-7500.

Conclusion

This class action lawsuit could present a vital opportunity for Geron investors to reclaim their losses. It's crucial for affected shareholders to be aware of the deadline and to take action promptly to secure their interests.

For additional insights and updates regarding the ongoing case, as well as their rights as investors, professionals encourage shareholders to monitor developments surrounding Geron Corporation closely.